Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04340180 · ClinicalTrials.gov registry record · Phase 1
Evaluating the Performance of AI in Evaluating Breast MRI Performed With Dose Reduction
A Phase 1 study, sponsored by University of Alabama at Birmingham.
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT04340180 is a Phase 1 study that has completed, run by University of Alabama at Birmingham. The registered enrollment target is 20 participants.
The verdict
NCT04340180, a Phase 1 study, has completed, sponsored by University of Alabama at Birmingham.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the ability of AI to correctly aid in characterization of benign and malignant lesions even when a low dose of gadolinium is administered. This study is relevant for several reasons, most notably being the reduction of MRI dose and decreased gadolinium deposition in the brain. In addition, use of AI may provide increased sensitivity and specificity for the radiologist evaluating a breast MRI exam. Half of the population will have benign pathologies and the other half will have malignant pathologies.
Interventions
- DRUG Standard of Care (SOC) gadolinium Breast MRI
- DRUG reduced 1/4 dose gadolinium Breast MRI with Artificial Intelligence (AI) to aid in evaluation.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2021-07-14 |
| Est. Completion | 2026-01-20 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04340180
The ClinicalTrials.gov registry entry for NCT04340180 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Standard of Care (SOC) gadolinium Breast MRI is the first listed.
NCT04340180 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04340180 about?
NCT04340180 is a clinical study titled "Evaluating the Performance of AI in Evaluating Breast MRI Performed With Dose Reduction". The purpose of this study is to evaluate the ability of AI to correctly aid in characterization of benign and malignant lesions even when a low dose of gadolinium is administered. This study is relevant for several reasons, most notably being the reduction of MRI dose and decreased gadolinium deposi...
What is the current status of trial NCT04340180?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2021-07-14. Estimated completion is 2026-01-20.
What interventions are being tested in trial NCT04340180?
The interventions under investigation include: Standard of Care (SOC) gadolinium Breast MRI (DRUG), reduced 1/4 dose gadolinium Breast MRI with Artificial Intelligence (AI) to aid in evaluation. (DRUG).
Who is sponsoring clinical trial NCT04340180?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.